Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
Clinical trial NCT05244798 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05244798
- Sponsor
- Sichuan Cancer Hospital and Research Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-01
- Primary completion
- 2025-12-31
- Enrollment
- 420
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.